Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension

Wiener Klinische Wochenschrift

Volumn 118, Issue 1-2, 2006, Pages 54-59

  Halank, Michael ^a,d   Kolditz, Martin ^a   Opitz, Christian ^b   Hoeffken, Gert ^a   Ewert, Ralf ^c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b DRK KLINIKEN BERLIN WESTEND   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Bosentan; Idiopathic pulmonary arterial hypertension; Iloprost; Pulmonary hypertension; Sildenafil

Indexed keywords

BOSENTAN; ILOPROST; SILDENAFIL;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOSE RESPONSE; FEMALE; HUMAN; IDIOPATHIC DISEASE; PULMONARY HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; INJECTIONS, INTRAVENOUS; MIDDLE AGED; PATIENT SELECTION; PIPERAZINES; PULMONARY ARTERY; SULFONAMIDES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33644821677     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-005-0507-8     Document Type: Article

References (28)

1. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115: 343-349
2. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al (1987) Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107: 216-223
3. Rich S (1998) World Symposium on Primary Pulmonary Hypertension 1998: Executive Summary, www.who.int/ncd/cvd/pph.html
4. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al (2004) Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol 43: 5-12
5. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334: 296-302
6. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L (1998) Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmo-nary hypertension. Heart 80: 151-155
7. British Cardiac Society Guidelines and Medical Practice Committee, and approved by the British Thoracic Society and the British Society of Rheumatology (2001) Recommendations on the management of pulmonary hypertension in clinical practice. Heart 86 [Suppl 1]: 11-13
8. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W (1996) Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 124: 820-824
9. Olschewski H, Rohde B, Behr J, Ewert R, Gessler T, Ghofrani HA, et al (2003) Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 124: 1294-1304
10. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347: 322-329
11. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al (2004) Task Force Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 25: 2243-2278
12. Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A, et al (2004) Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24: 353-359
13. Wensel R, Opitz C, Anker SD, Winkler J, Hoeffken G, Kleber, et al (2002) Assessment of survival in patients with primary pulmonary hypertension. Importance of cardiopulmonary exercise testing. Circulation 106: 319-324
14. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40: 780-788
15. L McLaughlin VV, Shillington A, Rich S (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106: 1477-1482
16. Kähler CM, Graziadei I, Wiedermann CJ, Kneussl MP, Vogel W (2000) Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension. Wien Klin Wochenschr 112: 637-640
17. Higenbottam TW, Butt AY, Dinh-Xaun AT, Takao M, Cremona G, Akamine S (1998) Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 79: 175-179
18. Grant SM, Goa KL (1992) Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischemia and extracorporal circulation procedures. Drugs 43: 889-924
19. Opitz CF, Wensel R, Bettmann M, Schaffarczyk R, Linscheid M, Hetzer R, et al (2003) Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 24: 356-365
20. Wensel R, Opitz C, Ewert R, Bruch L, Kleber FX (2000) Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation 101: 2388-2392
21. Olschewski H, Ghofrani A, Schmehl T, Winkler J, Wilkens H, Höper MM, et al (2000) Inhaled Iloprost to treat severe pulmonary hypertension. Ann Intern Med 132: 435-443
22. Molnar C, Alber H, Colleslli D, Vogel W, Kähler CM (2004) Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis. Wien Klin Wochenschr 116: 627-630
23. Hoeper MM, Spiekerkoetter E, Westerkamp V, Gatzke R, Fabel H (2002) Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. Eur Respir J 20: 339-343
24. Kim NH, Channick RN, Rubin LJ (2003) Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest 124: 1612-1615
25. Schenk P, Petkov V, Madl C, Kramer L, Kneussl M, Ziesche R, et al (2001) Aerosolized iloprost therapy could not replace long-term IV epoprostenonol (prostacyclin) administration in severe pulmonary hypertension. Chest 119: 296-300
26. Suleman N, Frost AE (2004) Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Chest 126: 808-815
27. Ivy DD, Doran A, Claussen L, Bingaman D, Yetman A (2004) Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 93: 943-946
28. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J (2005) Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26: 858-63